20:39 , Jul 7, 2017 |  BC Week In Review  |  Company News

Arrien out-licenses RORgammaT series and autoimmune candidate ARN-6039

Arrien Pharmaceuticals LLC (Salt Lake City, Utah) granted an undisclosed pharmaceutical company worldwide rights to ARN-6039 and a series of compounds targeting RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT). Arrien said the target is...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

ARN-6039: Phase I started

Arrien began a 1-year, double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of oral ARN-6039 in about 50 healthy volunteers. Arrien Pharmaceuticals LLC, Salt Lake City, Utah   Product: ARN-6039   Business: Autoimmune...